# UNIVERSITY OF BIRMINGHAM

## University of Birmingham Research at Birmingham

# Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases

Sloan, Melanie; Wincup, Chris; Harwood, Rupert; Pollak, Thomas A; Massou, Efhalia; Bosley, Michael; Pitkanen, Mervi; Zandi, Michel S; Leschziner, Guy; Barrere, Colette; Ubhi, Mandeep; Andreoli, Laura; Brimicombe, James; Diment, Wendy; Jayne, David; Gordon, Caroline; Naughton, Felix; D'Cruz, David P

[Link to publication on Research at Birmingham portal](#)

**Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases: an international mixed methods study**

Melanie Sloan[1], Chris Wincup[2], Rupert Harwood[3], Thomas A. Pollak[4], Efhalia Massou[1], Michael Bosley[5], Mervi Pitkanen[4], Michael S. Zandi[6], Guy Leschziner[7], Colette Barrere[5], Mandeep Ubhi[8], Laura Andreoli[9,10], James Brimicombe[1], Wendy Diment[5], David Jayne[11], Caroline Gordon[8], Felix Naughton[12], David D'Cruz[13]

1. Department of Public Health and Primary Care Unit, University of Cambridge, Cambridge, UK
2. Department of Rheumatology, King's College Hospital London, London, UK
3. Swansea University Medical School, Swansea University, Swansea, Wales
4. Institute of Psychiatry, Psychology and Neuroscience, King's College London, and SLAM NHS Foundation Trust, London, UK
5. Patient Co-Investigators
6. Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK
7. Department of Neurology, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK
8. Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
9. Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy
10. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
11. Department of Medicine, University of Cambridge, Cambridge, UK
12. Behavioural and Implementation Science Group, School of Health Sciences, University of East Anglia, Norwich, UK
13. The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK

**Corresponding author:** Melanie Sloan

Department of Public Health & Primary Care, Forvie Site, Cambridge Biomedical Campus, Cambridge, CB2 0SR, UK

mas229@medschl.cam.ac.uk

**ABSTRACT**

**Objective**: A limited range of neuropsychiatric symptoms have been reported in systemic autoimmune rheumatic diseases (SARDs), with varied symptom prevalence. This study aimed to investigate a wider range of potential symptoms than previous studies, compare patient self-reports with clinician estimates, and explore barriers to symptom identification.

**Methods**: Mixed methods were used. Data from SARDs patients (n=1853) were compared with controls (n=463) and clinicians (n=289). In-depth interviews (n=113) were analysed thematically. Statistical tests compared means of survey items between: patients and controls, 8 different SARD groups, and clinician specialities.

**Results**: Self-reported lifetime prevalences of all 30 neuropsychiatric symptoms investigated (including cognitive, sensorimotor and psychiatric) were significantly higher in SARDs than controls. Validated instruments assessed 55% of SARDs patients as currently having depression and 57% anxiety. Barriers to identifying neuropsychiatric symptoms included: 1) limits to knowledge, guidelines, objective tests, and inter-specialty cooperation; 2) subjectivity, invisibility and believability of symptoms; and 3) under-eliciting, under-reporting and under-documenting. A lower proportion of clinicians (4%) reported never/rarely asking patients about mental health symptoms than the 74% of patients who reported never/rarely being asked in clinic (p<0.001). Over 50% of SARDs patients had never/rarely reported their mental health symptoms to clinicians; a proportion under-estimated at <10% by clinicians (p<0.001).

**Conclusion**: Neuropsychiatric symptom self-reported prevalences are significantly higher in SARDs than controls, and greatly underestimated by most clinicians. Research relying on medical records and current guidelines is unlikely to accurately reflect patients' experiences of neuropsychiatric symptoms. Improved inter-specialty communication and greater patient involvement is needed in SARD care and research.

**Key messages:**

1. The range of neuropsychiatric symptoms experienced by SARD patients is wider than previously reported.

2. Existing criteria are not reflective of patient experiences, contributing to widespread under-identification of neuropsychiatric symptoms.

3. Greater inter-speciality and clinician-patient collaboration is required in care, research and assessment criteria design.

**Introduction**

Neuropsychiatric (NP) symptoms in Systemic Autoimmune Rheumatic Disease (SARD) patients are associated with increased morbidity and mortality [1], and reduced quality of life [2]. Although multiple studies have estimated the prevalence of a range of NP symptoms, particularly depression and anxiety, in a variety of SARDs [2-4], prevalence findings vary considerably [5]. There are also gaps in the SARD literature regarding a wider range of potential NP symptoms, such as psychiatric, neuro-ophthalmological, auditory-vestibular and peripheral nervous system (PNS) symptoms. Aside from systemic lupus erythematosus (SLE), where neuropsychiatric lupus (NPSLE) has been more widely researched [1, 6, 7], research on a range of NP symptoms in several SARDs is very limited, particularly undifferentiated connective tissue disease (UCTD) and polymyalgia rheumatica (PMR) [4]. Gaps in the literature are also apparent concerning the identification/non-identification of NP SARD symptoms in clinical practice, with, for example, little on the extent to which clinicians ask SARD patients about NP symptoms.

Identifying NP symptoms as SARD symptoms can assist in diagnosis and disease management [8]. However, the diverse range of potential symptoms, limited biomarkers to assist in assessing causation [9], and a lack of understanding as to aetiology [10], can inhibit identification. Attribution is complicated by SARD patient quality of life usually being substantially adversely altered [2, 11], and therefore some NP symptoms such as depression may have varying levels of a reactive component, or be multifactorial in origin [3]. Medications can also have adverse NP impacts, particularly corticosteroids [12].

In addition, it seems possible that studies have in general underestimated SARD NP symptom range and prevalence in part as the result of symptom exclusion. For example, although the Systemic Lupus International Collaborating Clinics (SLICC) group, and the Italian Society of Rheumatology Study Group on NPSLE have substantially furthered understanding of NP symptoms in SLE, [6, 7, 13, 14], study symptom inclusion is usually restricted to only the 19 symptoms listed in the American College of Rheumatology (ACR) criteria[14]. Moreover, due to prevalence studies frequently relying upon what patients report to clinicians[15], eliciting/reporting biases and misattribution biases could also have an

impact and may be generating an under-estimation of the NP symptom burden in all SARDs. Patients may, for example, be reluctant to report NP symptoms to their clinicians for fear of being labelled with a primary psychiatric diagnosis [15, 16].

To address the identified gaps in the literature this study therefore elicited and compared patient-reported and clinician-estimated prevalences of a much broader range (n=30) of potential NP symptoms than has been previously studied, and identified reasons for their under-identification by clinicians and in research.

## Methods

### INSPIRE Project

The INSPIRE (**I**nvestigating **N**europsychiatric **S**ymptom **P**revalence and **I**mpact in **R**heumatology patient **E**xperiences) research project consists of a series of inter-related mixed method studies exploring various aspects of SARD NP symptoms identified by patient groups and clinicians as of key importance to investigate. The quantitative and qualitative methods have been applied and integrated at every stage of the research process to complement the respective methodological strengths [17]. More details on the methodology are in Supplementary Data S1 (available at *Rheumatology* online), including symptom descriptions, recruitment and data analysis information, and the STROBE and COREQ[18] checklists.

### Participants and design

Preparatory work with patients and clinicians ensured the survey incorporated a broad range (n=30) of NP symptoms. The final pre-tested surveys were made available between July 2022 and September 2022 (patients) or November 2022 (clinicians) internationally on the online platform Qualtrics, via social media, patient support groups and professional networks, with the following criteria specified:

Inclusion criteria for patients: 18 years and over, and reporting a SARD(s) confirmed in a clinical correspondence. Any SARD groups with n>50 participants were included in the study.

Inclusion criteria for clinicians: Clinicians in the following specialisms were explicitly invited to participate: rheumatology, neurology, psychiatry and primary care. Other clinicians were eligible if they had involvement with rheumatology patients' NP symptoms.

Controls were recruited by asking patient respondents to forward the control survey link to a friend with the following exclusion criteria provided: <18 years old or any serious incurable physical disease. It was made clear that having a mental health condition (however severe) did not make the person ineligible. Advantages of using 'healthy friend' controls include convenience and the increased likelihood of case-control sociodemographic similarities [19].

4

To reduce differing interpretations for symptoms, identical lay terminology and explanations were used for patient, control and clinician surveys. In addition to demographic information, patients and controls were asked for frequency of having experienced each symptom (in their lives) from 5 options: Never, 1-3 times, >3 times but not often, often, always. Clinicians were asked to estimate the lifetime prevalence of NP symptoms in all SLE patients (not just their own patients). Questions on eliciting and reporting of symptoms used a 7 item Likert-type scale of increasing frequency from 0=never to 6=always. Validated instruments were included in the surveys to ascertain current levels of depression (PROMIS SF8b) and anxiety (GAD-7) [20]. Interviews - with interviewees purposively selected to cover a range of socio-demographic and experience characteristics - were conducted by three experienced medical researchers and lasted from 28 minutes to >3 hours.

**Analysis**

Differences between and within the groups of interest (i.e. patients, controls and clinicians) were investigated using t-tests, analysis of variance (ANOVA) and Kruskal Wallis (KW) tests, based on the distribution and the type of data. Post-hoc tests were used where statistically significant differences were revealed. Correlations were calculated using Spearman's or Pearson's as appropriate, and chi-square tests were used to investigate the associations between variables of interest. Adjusted logistic regression models were used to investigate the differences in outcomes between the SARDs groups. P=0.05 was used as the minimum significance. For comparing patients and controls, lifetime prevalence was defined as a participant reporting experiencing that symptom >3 times in their lives to exclude the occasional experience of common symptoms such as low mood and anxiety. SLE was selected for comparing patient self-reported NP symptoms with clinician estimates due to it being the SARD most commonly associated with NP symptoms. For this patient-clinician comparison, prevalence was defined as the patient ever having experienced a symptom.

The qualitative analysis used data from open-ended survey questions and in-depths interviews. Analysis was thematic and broadly followed Braun and Clarke's stages of analysis[21, 22]. This includes: 1) immersion in the data; 2) developing a coding (categorisation) scheme, and coding; 3) combining participant extracts for each code; and 4) generating themes directly from the data using the codes, and with input on interpretation from the wider study team. Addressing threats to validity included testing and developing emergent findings against additional data, triangulating qualitative and quantitative results, and discussion of conflicting views. Using a constructionist[23] qualitative paradigm also ensured the resultant themes were co-constructed between the study team and study participants.

**Ethical approval**

Ethical approval was obtained through the Cambridge Psychology Research Committee: PRE 2022.027. Informed consent was taken electronically at the start of the online surveys and recorded verbally on audio-recordings for interviews. The protocol and statistical analysis plan were pre-registered: https://osf.io/zrehm .

**Results**

This study reports on data analysed from 2,605 UK and international respondent (patients =1853, clinicians =289, controls =463) surveys, and interviews with 67 patients and 46 clinicians (Table 1). SARD groups included were: SLE, inflammatory arthritis (IA), vasculitis, Sjögrens, polymyalgia rheumatica (PMR), undifferentiated connective tissue disease (UCTD), myositis and systemic sclerosis (SSc). Participants selecting mixed/multiple SARDs on the survey were included in the combined SARD calculations. Clinician respondents (70% of whom were at consultant level) mainly composed of rheumatologists (48%), psychiatrists (25%), and neurologists (13%). Additional participant details are in Supplementary Table S1, available at *Rheumatology* online.

**Table 1. Participant characteristics**

| Characteristic | Patient survey (n=1853) (%) | Patient interviews (n=67) (%) | Control survey (n=463)(%) | Clinician survey (n=289)(%) | Clinician interviews (n=46)(%) |
|---|---|---|---|---|---|
| **Age** | | | | | |
| 18- 30 | 94 (5%) | 6 (9%) | 45 (10%) | 6 (2%) | 0 |
| 30-39 | 195 (11%) | 5 (7%) | 71 (15%) | 90 (31%) | 8 (17%) |
| 40-49 | 298 (16%) | 17 (25%) | 82 (18%) | 95 (33%) | 19 (41%) |
| 50-59 | 519 (28%) | 16 (24%) | 84 (18%) | 60 (21%) | 11 (24%) |
| 60-69 (60+ for clinicians) | 478 (26%) | 9 (13%) | 120 (26%) | 38 (13%) | 8 (17%) |
| 70+ | 267 (14%) | 14 (21%) | 60 (13%) | N/A | N/A |
| Prefer not to say | 2 (<1%) | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) |
| | | | | | |
| **Gender** | | | | | |
| Female | 1687 (91%) | 60 (90%) | 334 (72%) | 153 (53%) | 22 (48%) |
| Male | 160 (9%) | 7 (10%) | 126 (27%) | 131 (45%) | 24 (52%) |
| Other/undisclosed | 6 (<1%) | 0 (0%) | 3 (<1%) | 5 (2%) | 0 (0%) |
| | | | | | |
| **Country/region** | | | | | |
| England | 1285 (69%) | 38 (57%) | 341 (74%) | 126 (44%) | 27 (59%) |
| Scotland | 144 (8%) | 7 (10%) | 43 (9%) | 14 (5%) | 2 (4%) |
| Wales | 104 (6%) | 7 (10%) | 20 (4%) | 4 (1%) | 2 (4%) |
| N. Ireland or Republic of Ireland | 35 (2%) | 3 (4%) | 7 (2%) | 0 (0%) | 0 (0%) |
| US or Canada | 112 (6%) | 4 (6%) | 16 (3%) | 47 (16%) | 3 (7%) |
| Europe | 121 (7%) | 4 (6%) | 24 (5%) | 47 (16%) | 5 (11%) |
| Asia | 18 (1%) | 1 (1%) | 1 (<1%) | 17 (6%) | 3 (7%) |
| Latin America | 4 (<1%) | 0 (0%) | 2 (<1%) | 21 (7%) | 3 (7%) |
| Australia or New Zealand | 19 (1%) | 2 (3%) | 0 (0%) | 6 (2%) | 0 (0%) |
| Other | 11 (<1%) | 1 (1%) | 9 (2%) | 7 (2%) | 1 (2%) |
| | | | | | |
| **Ethnicity** | | | | | |
| White | 1718 (93%) | 56 (84%) | 434 (95%) | | |
| Asian | 49 (3%) | 7 (10%) | 6 (1%) | | |
| Black | 23 (1%) | 2 (3%) | 4 (1%) | | |
| Mixed | 40 (2%) | 2 (3%) | 11 (2%) | | |
| Other/Undisclosed | 23 (1%) | 0 (0%) | 2 (<1%) | | |
| | | | | | |
| **Disease** | | | | | |
| SLE | 566 (31%) | 25 (37%) | | | |
| Inflammatory arthritis | 456 (25%) | 9 (13%) | | | |
| Vasculitis | 200 (11%) | 3 (4%) | | | |
| Sjögrens | 150 (8%) | 6 (9%) | | | |
| PMR | 132 (7%) | 7 (10%) | | | |
| UCTD | 77 (4%) | 9 (13%) | | | |
| Myositis | 64 (4%) | 3 (4%) | | | |
| Systemic sclerosis | 63 (3%) | 2 (3%) | | | |
| Mixed/multiple | 145 (8%) | 3 (4%) | | | |
| | | | | | |
| **Clinician Role** | | | | | |
| Rheumatologist | | | | 139 (48%) | 20 (43%) |
| Psychiatrist | | | | 72 (25%) | 7 (15%) |
| Neurologist | | | | 38 (13%) | 7 (15%) |
| Rheumatology nurse | | | | 17 (6%) | 4 (9%) |
| GP/Primary care | | | | 11 (4%) | 5 (11%) |
| Other speciality | | | | 12 (4%) | 3 (7%) |

7

**Section 1: Symptom prevalence**

**1.1 SARD patient and control self-reported NP symptoms**

SARD patients had a significantly higher lifetime self-reported prevalence (experienced >3 times in their life) of all NP symptoms compared to controls (Figures 1-2), including after adjusting for age, gender, ethnicity and country of residence (Supplementary Table S2, available at *Rheumatology* online). Symptoms with the highest prevalence in SARDs were fatigue (mean SARD prevalence of 89% versus 34% in controls), insomnia (76% versus 49%) and cognitive dysfunction (70% versus 22%). PMR patients reported the lowest prevalence of NP symptoms, and SLE and UCTD patients the highest. There were significant differences in symptom frequency between males and females for 18/30 of the symptoms (11/30 were significantly more frequently experienced by females). There were weak negative correlations (maximum of r= -0.250, p<0.001 (for OCD)) between age and symptom frequency for all symptoms except for insomnia. More detailed statistics can be found in Supplementary Tables S3-S5, available at *Rheumatology* online).

Aside from in SLE where widespread neuropsychiatric effects were more expected, clinicians generally expressed surprise when shown the high prevalence and range of NP symptoms reported by all SARD groups. Opinions ranged from: '*they don't commonly affect the brain*' (Ppt 191, Rheumatologist, England) to views that nervous system involvement was more common than currently recognised:

> '*All these autoimmune inflammatory rheumatological diseases, they all affect the brain to a greater or lesser degree...* [some clinicians] *are not getting this right to have as primarily a joint problem and not consider the neuropsychiatric*' (Ppt 115, Psychiatrist, US)

8

**Figure 1. Lifetime self-reported prevalence of potential neuropsychiatric symptoms in SARD's compared to controls.** Percentage of controls and each disease group experiencing each symptom (>3 times in their lives) in descending order of SARDs frequency. Highest (orange) and lowest (green) prevalences are highlighted. Chi squared results are from the comparison of the individual SARD groups. Note: The combined SARDs group and chi squared comparison included the 8 individual SARDs listed plus participants with mixed or multiple connective tissue diseases/SARDs.

| | Controls % (n=418) | Combined SARDs % (n=1813) | SLE % (n=548) | RA/IA % (n=450) | Vasculitis % (n=196) | Sjögrens % (n=149) | PMR % (n=130) | UCTD % (n=76) | SSc % (n=63) | Myositis % (n=63) | Chi Square p-values |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue | 34 | 89 | 94 | 86 | 89 | 93 | 81 | 91 | 87 | 89 | <0.001 |
| Insomnia | 49 | 76 | 79 | 75 | 74 | 83 | 74 | 83 | 68 | 73 | 0.056 |
| Cognitive dysfunction | 22 | 70 | 82 | 66 | 62 | 77 | 52 | 78 | 57 | 57 | <0.001 |
| Weakness/loss of strength | 13 | 63 | 64 | 57 | 60 | 60 | 61 | 70 | 73 | 84 | 0.002 |
| Bowel or bladder problems | 31 | 61 | 66 | 54 | 59 | 76 | 46 | 71 | 71 | 59 | <0.001 |
| Anxiety | 41 | 59 | 68 | 56 | 58 | 62 | 39 | 74 | 49 | 49 | <0.001 |
| Restlessness/ agitation | 32 | 57 | 67 | 52 | 57 | 53 | 42 | 68 | 44 | 49 | <0.001 |
| Positive sensory symptoms | 20 | 56 | 63 | 47 | 63 | 60 | 40 | 66 | 49 | 57 | <0.001 |
| Very Low Mood | 35 | 56 | 66 | 55 | 55 | 52 | 38 | 59 | 51 | 48 | <0.001 |
| Hypersensitivity to noise and/or light | 18 | 55 | 67 | 44 | 47 | 65 | 35 | 72 | 43 | 41 | <0.001 |
| Palpitations | 27 | 55 | 62 | 48 | 55 | 54 | 43 | 70 | 63 | 46 | <0.001 |
| Loss of coordination/ balance | 14 | 51 | 57 | 49 | 48 | 55 | 33 | 58 | 41 | 65 | <0.001 |
| Dizziness/ raised HR on standing | 28 | 50 | 56 | 44 | 52 | 54 | 35 | 62 | 51 | 46 | <0.001 |
| Disrupted dreaming sleep | 31 | 48 | 57 | 42 | 47 | 50 | 38 | 57 | 37 | 41 | <0.001 |
| Tinnitus | 28 | 47 | 47 | 46 | 43 | 50 | 44 | 55 | 48 | 48 | 0.706 |
| Severe headache | 23 | 46 | 59 | 40 | 39 | 46 | 28 | 62 | 30 | 30 | <0.001 |
| Disorientation | 16 | 37 | 47 | 32 | 35 | 38 | 19 | 39 | 27 | 25 | <0.001 |
| Difficulty swallowing | 9 | 36 | 39 | 25 | 29 | 66 | 14 | 37 | 71 | 67 | <0.001 |
| Negative sensory symptoms | 8 | 32 | 38 | 29 | 31 | 36 | 18 | 34 | 32 | 37 | 0.001 |
| Visual changes | 9 | 31 | 36 | 27 | 37 | 34 | 20 | 34 | 21 | 30 | 0.002 |
| Uncontrollable emotions | 14 | 30 | 39 | 26 | 30 | 16 | 27 | 26 | 16 | 32 | <0.001 |
| Obsessive thoughts or compulsive behaviour | 17 | 27 | 36 | 23 | 26 | 23 | 12 | 37 | 22 | 24 | <0.001 |
| Tremors | 7 | 24 | 30 | 18 | 27 | 25 | 18 | 36 | 16 | 22 | <0.001 |
| Hearing loss | 8 | 23 | 23 | 20 | 35 | 30 | 12 | 21 | 22 | 14 | <0.001 |
| Suicidal thoughts | 12 | 19 | 23 | 16 | 18 | 17 | 12 | 25 | 16 | 21 | 0.043 |
| Mania | 8 | 16 | 20 | 13 | 15 | 11 | 12 | 12 | 17 | 14 | 0.011 |
| Disinhibition | 9 | 16 | 18 | 13 | 19 | 13 | 8 | 21 | 16 | 11 | 0.043 |
| Hallucinations | 4 | 11 | 15 | 7 | 12 | 8 | 4 | 16 | 17 | 13 | <0.001 |
| Delusions and/or paranoia | 5 | 8 | 11 | 7 | 9 | 5 | 3 | 11 | 10 | 6 | 0.127 |
| Seizures | 3 | 5 | 7 | 4 | 3 | 7 | 3 | 8 | 6 | 2 | 0.091 |

**Figure 2: Comparison of self-reported lifetime (experienced >3 times in life) prevalence of individual NP symptoms between SARD patients (n=1813) and healthy controls (n=418).**



## 1.2 Current levels of depression and anxiety

Current mean depression and anxiety scores were significantly higher for the combined SARD group than for controls (Table 2). Combined SARDs depression scores (using PROMIS SF8b) were 17.69 compared to 13.53 for controls (95%CI 3.41 to 4.90, p<0.001). There were significant differences between SARD groups (Kruskal Wallis = 36.97 (depression) and 69.45 (anxiety), both p<0.0001, (post-hoc tests in Supplementary Table S6, available at *Rheumatology* online), with PMR patients having the lowest levels of current anxiety (37%) and depression (39%). SLE patients had the highest levels of anxiety (70%) and UCTD patients the highest levels of depression (61%). There were no significant differences in anxiety and depression scores between male and female patients.

Converting into severity of depression, 55% of SARD patients had some degree of depression (mild=24%, moderate =25%, severe = 6%) compared to 30% of controls overall. Some level of anxiety (using GAD-7) was found in 57% of SARDs (mild =31%, moderate= 16%, severe =10%) compared to 33% of controls (Tables 2.2 and 2.4).

10

**1.3 SLE patient reported prevalence compared to clinician estimates.**

Clinician estimates of NP symptom prevalence were lower than SLE patient reports for all symptoms (Fig 3a). For example, 47% of SLE patients reported having (ever) experienced suicidal thoughts compared to the median clinician estimate of 15%. The lack of consensus and range of knowledge of NP symptoms was highlighted by the large range of frequency estimates between (Fig 3b), and within, specialities (Fig 3c; additional figures available as Supplementary Figure S1 at *Rheumatology* online). Patients were unanimously unsurprised when shown the large differences between patients and clinician estimates, stating it was because clinicians didn't always '*ask*' or '*listen*' and/or '*believe*' (multiple patients). In contrast, most clinicians expressed surprise and concern. Understanding the range and prevalence of symptoms from the patients' perspective was felt to be very valuable:

> *'It is very interesting because you haven't used just the symptoms in the published criteria and this has come from the patients, so it is important for us to know... I am worried now I have been under-estimating these symptoms in my patients'* (Ppt 200, Rheumatologist, Europe)

Psychiatrists' prevalence estimates were the closest to patient self-reports (Fig 3b), and were significantly higher than neurologists' and rheumatologists' estimates (except for fatigue and cognitive dysfunction). Participants surmised this was related to psychiatrists having more time and skill to sensitively elicit NP symptoms.

11

**Table 2 – Validated instrument scores for anxiety (GAD7) and depression (PROMIS- SF8b)**

| 2.1 Raw GAD-7 (anxiety) scores | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | Controls n=409 | Mean SARDs n=1581 | SLE n=458 | RA/IA n=396 | Vasculitis n=172 | Sjögrens n=132 | PMR n=123 | UCTD n=66 | SSc n=56 | Myositis n=58 |
| Raw GAD7 Scores* (Mean(SD) | 3.78 (4.36) | 6.50 (5.30) | 7.97 (5.51) | 6.16 (5.08) | 5.98 (5.33) | 5.68 (5.01) | 4.54 (4.94) | 6.5 (4.86) | 5.93 (5.21) | 5.81 (4.79) |
| **2.2 GAD-7 raw scores converted into severity of anxiety: % of each group (n)** | | | | | | | | | | |
| | Controls % n=409 | Mean SARDs % n=1581 | SLE % n=458 | RA/IA % n=396 | Vasculitis % n=172 | Sjögrens % n=132 | PMR % n=123 | UCTD % n=66 | SSc % n=56 | Myositis % n=58 |
| No Anxiety | 67 (273) | 43 (675) | 30 (136) | 44 (175) | 47 (81) | 50 (66) | 63 (78) | 39 (26) | 52 (29) | 47 (27) |
| Mild anxiety | 21 (87) | 31 (498) | 34 (155) | 33 (131) | 31 (54) | 28 (37) | 23 (28) | 36 (24) | 27 (15) | 34 (20) |
| Moderate anxiety | 9 (35) | 16 (253) | 22 (103) | 15 (58) | 12 (21) | 14 (18) | 6 (7) | 17 (11) | 14 (8) | 14 (8) |
| Severe anxiety | 3 (14) | 10 (155) | 14 (64) | 8 (32) | 9 (16) | 8 (11) | 8 (10) | 8 (5) | 7 (4) | 5 (3) |
| Any degree of anxiety | 33% (136) | 57% (906) | 70% (322) | 56% (221) | 52% (91) | 50% (66) | 37% (45) | 61% (40) | 48% (27) | 53% (31) |
| **2.3 Raw PROMIS SF8b (depression) scores** | | | | | | | | | | |
| | Controls n=412 | Mean SARDs n=1589 | SLE n=461 | RA/IA n=399 | Vasculitis n=172 | Sjögrens n=133 | PMR n=124 | UCTD n=66 | SSc n=56 | Myositis n=58 |
| Raw PROMIS depression scores SF8b** mean and (SD) | 13.25 (6.51) | 17.69 (8.11) | 19.21 (8.76) | 17.58 (7.90) | 17.08 (7.78) | 16.47 (7.47) | 14.73 (6.82) | 18.55 (8.14) | 16.48 (7.82) | 16.48 (7.88) |
| **2.4 PROMIS raw scores converted into severity of depression: % of each group (n)** | | | | | | | | | | |
| | Controls % n=412 | Mean SARDs % n=1589 | SLE % n=461 | RA/IA % n=399 | Vasculitis % n=172 | Sjögrens % n=133 | PMR % n=124 | UCTD % n=66 | SSc % n=56 | Myositis % n=58 |
| No depression | 70 (290) | 45 (720) | 41 (188) | 43 (171) | 47 (81) | 50 (67) | 61 (76) | 39 (26) | 45 (25) | 57 (33) |
| Mild depression | 14 (59) | 24 (372) | 21 (98) | 29 (114) | 22 (37) | 23 (30) | 22 (27) | 24 (16) | 25 (14) | 16 (9) |
| Moderate depression | 15 (60) | 25 (402) | 29 (133) | 22 (89) | 27 (46) | 24 (32) | 15 (18) | 30 (20) | 26 (15) | 24 (14) |
| Severe depression | 1 (3) | 6 (95) | 9 (42) | 6 (25) | 5 (8) | 3 (4) | 2 (3) | 6 (4) | 4 (2) | 3 (2) |
| Any degree of depression | 30% (122) | 55% (869) | 59% (273) | 57% (228) | 53% (91) | 50% (66) | 39% (48) | 61% (40) | 55% (31) | 43% (25) |

*Min=0, Max=21 regardless of the group; Statistically significant difference in the mean anxiety score between the control and the SARDs groups based on the t-test (95% CI) p<0.05(2.16, 3.27); Statistically significant difference in the mean anxiety score across the individual disease categories, based on Kruskal-Wallis test KW=69.45, p<0.05. The post-hoc test are given in Table A7. The significant differences were robust when adjusting for age, gender, ethnicity, country.

** Min= 8, Max= 40 regardless of the group; Statistically significant difference in the mean depression score between the control and the SARDs groups based on the t-test (95% CI), p <0.05 (3.41, 4.90); Statistically significant difference in the mean depression score across the individual disease categories, based on Kruskal Wallis test KW= 36.97, p<0.05; The post-hoc test are given in Table A7. The significant differences were not robust when adjusting for age, gender, ethnicity, country.

**Figure 3. Lifetime (ever experienced) prevalence of NP symptoms in SLE – patient self-reports (n=548) compared to clinician estimates (n=246).** A) Patient self-reported prevalence compared to (median) clinician estimates. B) Estimates of prevalence subdivided into individual specialities with IQR. C) Example of large range of prevalence estimates for symptoms (using very low mood) by clinicians (n=246) Further examples in supplementary information 2, available at *Rheumatology* online.



13

**Section 2: Factors contributing to under-identification of NP symptoms**

The qualitative analysis indicated a range of factors (combined into 4 themes) had contributed to under-identification of NP symptoms: 1) Limitations to knowledge, assessment criteria and teamwork; 2) Subjectivity, invisibility and believability; 3) Under-eliciting, under-reporting and under-documenting; and 4) Describing and ascribing challenges.

**Theme 1. Limitations to knowledge, assessment criteria and inter-disciplinary teamwork**

Clinicians frequently reported no/limited training in, and knowledge of, many of the SARD NP manifestations listed in this study, and many stated they had '*guessed*' (multiple clinicians) estimates of symptom frequency. Some clinicians (and some patients) had not considered many of the surveyed NP symptoms to be potential or common manifestations of SARDs:

> '*I don't think we would ask about things like their hearing because that's not often related to lupus so similarly we wouldn't ask about mood*' (Ppt 4, Rheumatologist, England)

UCTD and Sjögren's patients in particular felt that their neurological symptoms were under-estimated. A common concern was that Sjögrens was assumed to be '*just dry eyes and mouth*' (multiple participants). Patients from all disease groups reported diverse NP symptoms which they perceived had sometimes been over-looked clinically, resulting in adverse repercussions, including permanent damage in some cases:

> *Nobody understands Sjögrens. My rheumatologist thinks it is a sicca disease only and refuses to even talk to me about all the neurological damage it has caused, continues to cause. I am now having to use a wheelchair as a result of advanced neuropathy* (Ppt 257, Sjögrens, England).

Several participants raised concerns that most rheumatological disease standard assessments, such as the Disease Activity Score (DAS) for rheumatoid arthritis, incorporated no neuropsychiatric assessments, and that some clinicians may be rigidly adhering to inadequate criteria. Current models for assessing and classifying NP symptoms even in SLE were considered to be too limited:

> '*Many* [SLE NP] *symptoms are under-estimated and not detected because they are not included in the main criteria like the ACR criteria. Something like small fibre neuropathy is very common we think but not tested often*' (Ppt 200, Rheumatologist, Europe)

Despite the acknowledged importance of multi-disciplinary teams (MDTs) for SARDs: '*the brain is such a complex organ it needs more than one brain working on it, more than one speciality*'. (Ppt 49, Psychiatrist, US), few clinicians and patients reported hospital systems facilitating effective multi-disciplinary teamwork. The psychiatrists discussed a much wider range of neuropsychiatric symptoms

14

potentially affecting SARD patients - such as derealisation, disinhibition, hypersensitivity to external stimuli - than the other specialities yet were very rarely consulted so were unable to help identify or manage these symptoms. There was strongly expressed disagreement about NP symptoms between and within specialties, and it was commonly felt that patients were often given '*contradicting messages*' (Ppt 287, Psychiatrist, Latin America) and missed or misdiagnoses. Rheumatology referral systems were compared unfavourably by neurologists and psychiatrists with more established multi-disciplinary working in diseases like MS and HIV. Rheumatology nurses were felt to be an asset, and their holistic focus more conducive to open reporting of NP symptoms: '*We are actually much more about them rather than how are your knees, your joints, skin…'(*Ppt 116, Rheumatology Nurse, Scotland).

Patients experiencing effective multi-disciplinary communication usually expressed a higher level of medical security:

> *Now my rheumatologist and psychiatrist talk to each other all the time…without those two I don't think I'd be functioning… never let me down* (Ppt 448, SLE, England)

**Theme 2: Subjectivity, invisibility and believability**

Clinicians widely acknowledged that many SARD NP symptoms are often not detectable using existing tests, even for symptoms that were perceived to be the most directly attributable to the SARD. Serology, cerebrospinal fluid (CSF) analysis, electromyographs (EMG) and brain imaging were reported to more frequently be normal than abnormal even in patients with severe SARD NP manifestations: '*We find normal brain MRIs in 70 to 80% of our NPSLE patients*' (Ppt 263, Rheumatologist, Asia)

However, access to and knowledge of tests (such as for cytokines, interferons or complement activation products) considered to be potentially more enlightening in detecting neuro-inflammation was reported to be very limited outside of research. Most clinicians therefore principally used tests to exclude infections and other non-SARD causes for NP symptoms. Only a minority of clinicians specified that tests must be abnormal for an NP symptom to be identified and to: '*count*' [it depended on] '*looking for that objective evidence*' (Ppt 76, Neurologist, England), and '*localising symptoms…that's what we do as neurologists*'. (Ppt 162, neurologist, England). Most clinicians felt that '*diffuse*' (multiple clinicians) NP symptoms were more common in systemic autoimmunity:

> '*These complex diseases, they often don't have clearly objective, localised symptoms so you need to look deeper and understand the connection between the central and the peripheral nervous systems, the immune system, and the gastrointestinal systems, the cardiovascular system. These patients often have interactions between all of these and that's what underlies that lack of localisation for these symptoms*' (Ppt 67, Neurologist, US)

15

Limited availability and accuracy of objective testing and the invisibility of many NP symptoms contributed to many patients feeling disbelieved:

> *'The rheumatologists that I have dealt with, actually only treat visible symptoms. That the symptoms that they can't see cannot be trusted to be the truth given by the patient'* (Ppt 83, Sjögrens, Wales)

Many patients and clinicians highlighted the importance of listening to and believing patient reports: *'Your first thought is not I'll do a blood test to check if they're telling the truth… you just sort of believe them'* (Ppt 57, Psychiatrist, England). Relying solely on subjective reports was complicated by some clinicians feeling that patients did not always understand or accurately report their NP symptoms. However, other clinicians felt that patients had more insight into these symptoms than they were sometimes given credit for:

> *'People who have these chronic diseases they really know their own body…patients know themselves and listening is most important and valuing their views will often be more enlightening, and if we don't listen then it's usually because we are afraid that we don't know enough'* (Ppt 79, Psychiatrist, England)

**Theme 3: Under-eliciting, under-reporting and under-documenting of NP symptoms**

A significantly lower proportion of clinicians reported never/rarely asking rheumatology patients about mental health (MH) symptoms compared to patients who reported they had never/rarely been asked about MH in clinic (4% vs 74%, p<0.001) (Fig 4a). This difference was discussed in interviews with some participants surmising that clinicians may have counted a general 'how are you?' as having asked the patient about their MH, whereas patients were expecting more specific questions as a follow-up to their - often polite and non-informative - initial response*: 'No-one asks probing questions, ''I'm fine'' type answers aren't questioned'* (Ppt 260, England, IA). Moderate positive correlations were found between frequencies of being explicitly asked about MH and reporting MH symptoms (r=0.38 for major MH and r=0.42 for minor MH, both p<0.001).

Over 50% of patients had never/rarely reported their MH symptoms to a clinician. Patient reporting frequencies were significantly different from clinician perceptions where clinician mean frequency estimate was 3.67 (on a scale of 0=never to 6=always) of reporting major MH symptoms compared to the patient mean of 1.79 (95% CI -2.14, -1.62, p<0.001) (Figure 4a). Patients from the US were significantly more likely than those from mainland UK to report MH symptoms to a clinician, and to report being asked about their mental health by clinicians (supplementary information 2, available at *Rheumatology* online).

Several clinicians stated that they did not ask about symptoms such as hallucinations and delusions because they would be unmissable, or they did not know how to approach the topic. Other clinicians and most patients identified extreme reticence and stigma associated with reporting such symptoms,

and the importance of asking explicitly: *'doctors don't go looking for it* [hallucinations] *so if we don't ask we don't think it exists much'* (Ppt 14, Rheumatology Nurse, England)

Aside from time constraints, the most frequently cited reasoning for non-disclosure was a fear of future disease symptoms being misattributed to MH, or a common experience of past disease symptoms being disbelieved or misattributed to psychological/psychogenic causes:

> *'During the start of my vasculitis I was told it was all in my mind and that I needed to think positively ...I buried my feelings after that'* (Ppt 423, Vasculitis, England)

Patients also frequently reported that even when they did share their NP symptoms, they were often not commented on and/or not documented accurately or at all. SARD Clinic letters and medical records were felt  often to be *'too brief'* (Ppt 7, GP, England) and to under-report the quantity and severity of symptoms reported: '*letters my rheumatologist writes that don't cover even half of what we talked about... ignores all my neurological symptoms'* (Ppt 52, UCTD, England). GPs and other specialists relied on information from rheumatologists, and also felt the focus was rarely on NP symptoms.

The under-documenting, under-eliciting and under-reporting appears to have contributed to a self-perpetuating cycle with researchers, clinicians and patients then being unaware of the possible NP symptoms to be covered in research, criteria and clinic (Fig 4b).

17

**Figure 4. Under-identification of neuropsychiatric symptoms in care and research.** A) Frequencies of eliciting and reporting mental health symptoms in clinician practice. SARD patients (n=1803) and clinicians (n=287). *At most, due to some patients not having MH concerns to report. ** paired t-test. ***0=Never to 6=Always. B) Model of movement between the cycles of NP symptom identification/non-identification.



| Category*** | Mean (± SD) patient frequencies N=1803* | Mean (± SD) clinician estimates N=287 | Mean Difference | 95% Confidence Interval | P Value** |
|---|---|---|---|---|---|
| Asked about MH symptoms in clinic | 1.08 (± 1.54) | 4.23 (± 1.86) | -3.14 | -3.34, -2.95 | <0.001 |
| Reporting of major MH concerns | 1.79 (± 1.89) | 3.67 (± 2.04) | -1.88 | -2.14, -1.62 | <0.001 |
| Reporting of minor MH concerns | 1.80 (± 1.75) | 3.66 (± 2.16) | -1.86 | -2.09, -1.62 | <0.001 |



Suggested movement towards a new cycle of symptom inclusion and identification, from the identified current self-perpetuating cycle of non-identification and non-inclusion of many NP symptoms, facilitated by ASKING about NP symptoms in clinic and INVOLVING patients in research.

**Theme 4: Describing and ascribing challenges**

Patients and clinicians discussed – and indeed demonstrated in interviews - difficulties in describing NP symptoms, arising from the absence of a clear and shared terminology:

> *'The way patients understand and use these words and the way we* [clinicians] *use these words can be a major limitation… [even] neurologists, rheumatologists and psychiatrists don't agree on the terminology and even if we do it's all very vague'* (Ppt 162, Neurologist, England)

Although the survey requested that symptom prevalence estimates not be influenced by opinions of the degree of attribution directly to the SARD, clinicians surmised that attribution considerations may have reduced identification in clinic and prevalence estimates by some clinicians: '*including in their* [prevalence] *assessments of whether it's 'organic''* (Ppt 76, Neurologist, England).

Regardless of the disparate views of attribution, the vast number of survey and interview responses describing decimated lives highlights the urgency of improving identification, and therefore support, for these often life-changing symptoms:

> *'Feel guilty and useless as well as depressed and very unwell. I don't really feel supported, understood, listened to, hopeful at all. It is awful living like this…. all just feels hopeless'* (Ppt 926, SLE, England)

**Discussion**

This mixed methods, international study found that the self-reported life-time prevalence of neuropsychiatric (NP) symptoms in multiple SARD patient groups was significantly higher than in the physically healthy controls, and under-estimated by most clinicians. Symptom identification was hindered by patients and clinicians often not being aware of the wide range of possible NP symptoms to raise these in clinic appointments, by clinicians not explicitly asking, and by patients being reluctant to report their NP symptoms. In addition, when patients did attempt to report their NP symptoms, some perceived that their reports were not always listened to, believed, discussed in detail, or documented. Our finding that >50% of SARDs patients never/rarely reported their NP symptoms to clinicians not only highlights the importance of clinicians explicitly asking about these symptoms in clinic, but also indicates the value of research obtaining symptom and other data directly from the patients. While self-reported prevalence rates are subject to other potential biases such as recall bias [24], research that relies solely on often inaccurate or incomplete [25] medical records and clinician assessments [1, 6] may be under-estimating NP symptom range and prevalence.

Whilst SARD NP prevalence estimates vary greatly between studies [5], the overall level and range of NP symptoms we identified was higher than indicated in the literature. Our patient data conflicted with

research reporting nervous system involvement as being "quite unusual" [26] in RA, "rare but not negligible" in Sjögrens [27], and suggesting that the ''central nervous system is one of the very few organs that is not involved'' in SSc [28]. Hallucinations and psychosis are rarely considered to be related to SARDs other than SLE aside from occasional case reports [29, 30], yet our data shows significantly higher self-reported prevalences of hallucinations than in controls in multiple other SARDs including systemic sclerosis, vasculitis and UCTD. There is very limited research into UCTD NP manifestations, yet self-reported prevalences were highest in the UCTD group for 16 out of 30 NP symptoms included in our study. Most clinicians felt their ability to identify NP symptoms was hindered by limited time, and the lack of specific biomarkers and diagnostic tests [5], and often normal investigations [31] in SARD NP disease. Identifying SARD NP symptoms therefore remains largely reliant on patient reports and clinician judgement [6, 31]. This is a concern given the identified under-reporting, and clinicians' extremely varied prevalence estimates and candour about their own, and other specialties, limitations in identifying SARDs NP symptoms. Identifying many NP SARD symptoms in clinic and research is therefore highly reliant on listening to, and believing, a patient's subjective reports[15]. This research highlights the importance of greater use of patient reported outcomes measures (PROMs) for subjective symptoms which can only be evaluated by the patient [32], such as headache and fatigue. Interviews indicated that psychiatrists' prevalence estimates being the closest to patient self-reports may reflect the ability to empathetically elicit and value subjective reports, although this may also have been influenced by longer appointments, and the majority of referrals to psychiatrists being for patients with the most severe symptoms. Psychiatrists could be a particularly valuable addition to more SARD patient's care, and in identifying the NP symptoms which are not currently (and some may never be) detectable using objective tests. In contrast, some clinicians prioritising objective test results and localisable symptoms may be hindering identification of the diffuse NP symptoms reported as more common in SARDs[1].

We suggest that there has been a self-perpetuating cycle, in which NP symptoms are under-elicited in clinic, under identified in research, excluded from trial outcomes[33], and have limited [14, 34] or non-inclusion in SARD criteria/guidelines [35]. Our data and clinician participants strongly endorse the calls to update the ACR NPSLE criteria [36, 37], which remains widely used despite being reported as having low reliability and "quite unsatisfactory" performance in clinical practice [6]. In addition, guideline development and care for other SARDs should give more consideration to NP symptoms. This may be facilitated by the greater 'multidisciplinary international collaborative research' [36] suggested to help meet NP SARD research goals, yet few of our clinician participants worldwide reported effective systems for inter-disciplinary clinical and academic collaboration between rheumatology, neurology and psychiatry. Our research has also demonstrated the importance of fully including the patients as equal collaborators [38-40], in line with EULAR guidance [41], and to ensure "change and innovation" [40]. Greater appreciation of this unique, yet currently under-utilised, patient knowledge [42] may reduce the under-estimations of NP manifestations we identified, the frequency of diagnostic errors [15, 42], and

20

ensure assessment criteria are more reflective of patients' actual experiences. Furthermore, although classification criteria were intended for selecting reasonably homogeneous patients for research purposes, many clinicians felt some colleagues were (and some demonstrated in interviews) misunderstanding and misusing them inflexibly in diagnosis, symptom identification and management.

This study also identified optimism for the future. Almost all clinicians were highly motivated to improve SARD NP care. Interviews and recent research demonstrates rapidly evolving NP knowledge including the behavioural and cognitive impacts of chronic inflammation [43] and a widening range of potential biomarkers [44], including serum interferon [45], CSF interleukins [46] and complement activation products [47]. Strengths of our study included that we endeavoured to incorporate the symptoms experienced by the patients, and of importance to them, by asking multiple SARD patient groups to list and discuss their NP symptoms prior to survey design. Our study psychiatrists also suggested that symptoms affecting other patient groups with autoimmune brain conditions[48], such as hypersensitivity and disinhibition, may be unrecognised SARD NP symptoms. We therefore included a much broader range of symptoms than has been previously researched rather than being constrained by previous SARD criteria. An additional strength of our research is the multi-disciplinary research team which includes patients as equally valued contributors, and ensures what is 'important to patients' [38] is prioritised.

This study was designed to encourage further exploration, discussion and inclusion of a greater range of SARD NP symptoms in research and clinic, rather than as an epidemiological survey to accurately assess prevalence. The methods used therefore had multiple limitations regarding generalisability including that responses were subject to recall bias [24], diagnoses were self-stated, and survey recruitment was via social media and professional networks. The self-selecting nature of online surveys may exclude the most unwell and the most disadvantaged, and may attract those with stronger opinions in both patient and clinician groups. Our survey also recruited a lower proportion of male patients and those from minority ethnic groups than is representative of the SARD population, as is common in rheumatological research.[49, 50] .In addition, controls may not have been representative of the general population, although common symptoms such as anxiety were similar to previously reported general population prevalences [20]. Clinician participants being largely recruited through twitter and professional networks may not be socio-demographically representative of the whole clinician population, and those choosing to complete surveys to be of patient benefit may be those with a more patient-centred focus. For example, the extreme difference between patients feeling they rarely/ never asked about MH (>70%) and clinician respondents having much lower values of never/rarely asking (<5%) may be partially due to the clinicians who were least interested in asking patients about MH also being the least likely to respond to a survey about MH symptoms. There was also no facility for ascertaining if the symptom was neuropsychiatric. For example, difficulty swallowing will be a neurological symptom in

some, but in other patients it may be as a result of fibrosis (e.g. in SSc) or lack of saliva production (e.g. in Sjögrens). Furthermore, although clinicians and patients were provided with identical lay descriptions of symptoms, in-depth interviews revealed that they had differing interpretations for some symptoms. This included in differentiating weakness from fatigue, and potentially in different use of terminology, such as symptoms or syndromes. Whilst our symptom list was more diverse and strived to be more reflective of the patient experiences than previous research, it was by no means exhaustive. Further limitations are included in Supplementary Data S1.

**Conclusion**

This study provides substantial evidence that the NP symptom burden is higher and more wide-ranging in the majority of SARDs than has previously been recognised, and that symptoms are often under-reported and under-recorded. More effective inter-disciplinary and patient-clinician collaboration is required to identify symptoms, and design criteria and research that is more reflective of the SARD NP symptoms experienced by patients.

The next stages of the INSPIRE (**I**nvestigating **N**europsychiatric **S**ymptom **P**revalence and **I**mpact in **R**heumatology patient **E**xperiences) project will investigate: attribution of NP symptoms, eliciting and reporting of NP symptoms, the impact of these symptoms on patient lives, and specific challenges and inequalities experienced by SARD patients from ethnic minorities.

23

**References:**

1. Hanly JG, Urowitz MB, Gordon C, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. *Ann Rheum Dis* 2020; 79: 356-362. 20200108. DOI: 10.1136/annrheumdis-2019-216150.

2. Fakra E and Marotte H. Rheumatoid arthritis and depression. *Joint Bone Spine* 2021; 88: 105200. 20210428. DOI: 10.1016/j.jbspin.2021.105200.

3. Figueiredo-Braga M, Cornaby C, Cortez A, et al. Depression and anxiety in systemic lupus erythematosus: The crosstalk between immunological, clinical, and psychosocial factors. *Medicine (Baltimore)* 2018; 97: e11376. DOI: 10.1097/MD.0000000000011376.

4. Manzo C, Nizama-Via A, Milchert M, et al. Depression and depressive symptoms in patients with polymyalgia rheumatica: discussion points, grey areas and unmet needs emerging from a systematic review of published literature. *Reumatologia* 2020; 58: 381-389. 20201223. DOI: 10.5114/reum.2020.102003.

5. Schwartz N, Stock AD and Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. *Nat Rev Rheumatol* 2019; 15: 137-152. DOI: 10.1038/s41584-018-0156-8.

6. Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. *Rheumatology (Oxford)* 2015; 54: 891-898. 20141021. DOI: 10.1093/rheumatology/keu384.

7. Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. *Arthritis Rheum* 2008; 59: 721-729. DOI: 10.1002/art.23566.

8. Carrion-Barbera I, Salman-Monte TC, Vilchez-Oya F, et al. Neuropsychiatric involvement in systemic lupus erythematosus: A review. *Autoimmun Rev* 2021; 20: 102780. 20210218. DOI: 10.1016/j.autrev.2021.102780.

9. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. *Autoimmun Rev* 2019; 18: 93-106. 20181105. DOI: 10.1016/j.autrev.2018.08.003.

10. McGlasson S, Wiseman S, Wardlaw J, et al. Neurological Disease in Lupus: Toward a Personalized Medicine Approach. *Front Immunol* 2018; 9: 1146. 20180606. DOI: 10.3389/fimmu.2018.01146.

11. Wallace ZS, Cook C, Finkelstein-Fox L, et al. The Association of Illness-related Uncertainty With Mental Health in Systemic Autoimmune Rheumatic Diseases. *J Rheumatol* 2022; 49: 1058-1066. 20220401. DOI: 10.3899/jrheum.211084.

12. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. *Psychiatry Clin Neurosci* 2011; 65: 549-560. DOI: 10.1111/j.1440-1819.2011.02260.x.

13. Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. *Semin Arthritis Rheum* 2011; 41: 1-11. 20101020. DOI: 10.1016/j.semarthrit.2010.08.001.

14. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum* 1999; 42: 599-608. DOI: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.

15. Sloan M, Naughton F, Harwood R, et al. Is it me? The impact of patient-physician interactions on lupus patients' psychological well-being, cognition and health-care-seeking behaviour. *Rheumatol Adv Pract* 2020; 4: rkaa037. 20200722. DOI: 10.1093/rap/rkaa037.

16. Badcock JC, Dehon H and Laroi F. Hallucinations in Healthy Older Adults: An Overview of the Literature and Perspectives for Future Research. *Front Psychol* 2017; 8: 1134. 20170707. DOI: 10.3389/fpsyg.2017.01134.

17. Creswell JW and Clark VLP. *Designing and conducting mixed methods research*. Sage publications, 2017.

18.     Tong A, Sainsbury P and Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007; 19: 349-357. 20070914. DOI: 10.1093/intqhc/mzm042.

19.     Bunin GR, Vardhanabhuti S, Lin A, et al. Practical and analytical aspects of using friend controls in case-control studies: experience from a case-control study of childhood cancer. *Paediatr Perinat Epidemiol* 2011; 25: 402-412. 20110719. DOI: 10.1111/j.1365-3016.2011.01210.x.

20.     Löwe B, Decker O, Müller S, et al. Validation and Standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the General Population. *Medical Care* 2008; 46: 266-274. DOI: 10.1097/MLR.0b013e318160d093.

21.     Braun V and Clarke V. *Thematic analysis*. American Psychological Association, 2012.

22.     Braun V and Clarke V. Reflecting on reflexive thematic analysis. *Qualitative research in sport, exercise and health* 2019; 11: 589-597.

23.     Rees CE, Crampton PES and Monrouxe LV. Re-visioning Academic Medicine Through a Constructionist Lens. *Acad Med* 2020; 95: 846-850. DOI: 10.1097/ACM.0000000000003109.

24.     Lovalekar M, Abt JP, Sell TC, et al. Accuracy of recall of musculoskeletal injuries in elite military personnel: a cross-sectional study. *BMJ Open* 2017; 7: e017434. 20171214. DOI: 10.1136/bmjopen-2017-017434.

25.     Donaldson L, Dezard V, Chen M, et al. Depression and generalized anxiety symptoms in idiopathic intracranial hypertension: Prevalence, under-reporting and effect on visual outcome. *J Neurol Sci* 2022; 434: 120120. 20211228. DOI: 10.1016/j.jns.2021.120120.

26.     Atzeni F, Talotta R, Masala IF, et al. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. *Best Pract Res Clin Rheumatol* 2018; 32: 500-510. 20190227. DOI: 10.1016/j.berh.2019.02.003.

27.     Massara A, Bonazza S, Castellino G, et al. Central nervous system involvement in Sjogren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. *Rheumatology (Oxford)* 2010; 49: 1540-1549. 20100505. DOI: 10.1093/rheumatology/keq111.

28.     Olah C, Schwartz N, Denton C, et al. Cognitive dysfunction in autoimmune rheumatic diseases. *Arthritis Res Ther* 2020; 22: 78. 20200415. DOI: 10.1186/s13075-020-02180-5.

29.     Shiraishi H, Koizumi J, Suzuki T, et al. Progressive systemic sclerosis with mental disorder. *Jpn J Psychiatry Neurol* 1991; 45: 855-860. DOI: 10.1111/j.1440-1819.1991.tb00524.x.

30.     Wong JK, Nortley R, Andrews T, et al. Psychiatric manifestations of primary Sjogren's syndrome: a case report and literature review. *BMJ Case Rep* 2014; 2014 20140523. DOI: 10.1136/bcr-2012-008038.

31.     Papadaki E, Fanouriakis A, Kavroulakis E, et al. Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. *Ann Rheum Dis* 2018; 77: 441-448. 20171219. DOI: 10.1136/annrheumdis-2017-212285.

32.     Clifford S, Taylor AJ, Gerber M, et al. Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts' Perspectives. *Value Health* 2020; 23: 104-113. 20200108. DOI: 10.1016/j.jval.2019.07.018.

33.     Silvagni E, Chessa E, Bergossi F, et al. Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review. *Rheumatology (Oxford)* 2021; 61: 8-23. DOI: 10.1093/rheumatology/keab324.

34.     Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjogren's Syndrome. *Rheumatology (Oxford)* 2017; 56: e24-e48. DOI: 10.1093/rheumatology/kex166.

35.     Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol* 2017; 69: 35-45. 20161026. DOI: 10.1002/art.39859.

36.     Hanly JG, Kozora E, Beyea SD, et al. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. *Arthritis Rheumatol* 2019; 71: 33-42. 20181124. DOI: 10.1002/art.40591.

37.    Bortoluzzi A, Scire CA and Govoni M. Comment on: Diagnosing and attributing neuropsychiatric events to systemic lupus erythematosus: time to untie the Gordian knot? *Rheumatology (Oxford)* 2017; 56: 856-857. DOI: 10.1093/rheumatology/kex017.
38.    Dures E, Hewlett S, Lord J, et al. Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study. *Patient* 2017; 10: 455-462. DOI: 10.1007/s40271-017-0221-4.
39.    Sloan M, Harwood R, Gordon C, et al. Will 'the feeling of abandonment' remain? Persisting impacts of the COVID-19 pandemic on rheumatology patients and clinicians. *Rheumatology (Oxford)* 2022; 61: 3723-3736. DOI: 10.1093/rheumatology/keab937.
40.    Nikiphorou E, Alunno A, Carmona L, et al. Patient-physician collaboration in rheumatology: a necessity. *RMD Open* 2017; 3: e000499. 20170718. DOI: 10.1136/rmdopen-2017-000499.
41.    de Wit MP, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. *Ann Rheum Dis* 2011; 70: 722-726. 20110120. DOI: 10.1136/ard.2010.135129.
42.    Blease CR and Bell SK. Patients as diagnostic collaborators: sharing visit notes to promote accuracy and safety. *Diagnosis (Berl)* 2019; 6: 213-221. DOI: 10.1515/dx-2018-0106.
43.    Bendorius M, Po C, Muller S, et al. From Systemic Inflammation to Neuroinflammation: The Case of Neurolupus. *Int J Mol Sci* 2018; 19 20181113. DOI: 10.3390/ijms19113588.
44.    Lindblom J, Mohan C and Parodis I. Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade. *Brain Sci* 2022; 12 20220130. DOI: 10.3390/brainsci12020192.
45.    Ramaswamy M, Tummala R, Streicher K, et al. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. *Int J Mol Sci* 2021; 22 20211019. DOI: 10.3390/ijms222011286.
46.    Yoshio T, Okamoto H, Kurasawa K, et al. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. *Lupus* 2016; 25: 997-1003. 20160203. DOI: 10.1177/0961203316629556.
47.    Zelek WM and Morgan BP. Targeting complement in neurodegeneration: challenges, risks, and strategies. *Trends Pharmacol Sci* 2022; 43: 615-628. 20220307. DOI: 10.1016/j.tips.2022.02.006.
48.    Easton A and Pollak T. Encephalitis matters. *Lancet Neurol* 2023 20230221. DOI: 10.1016/S1474-4422(23)00066-2.
49.    Lima K, Phillip CR, Williams J, et al. Factors Associated With Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Qualitative Systematic Review. *Arthritis Care Res (Hoboken)* 2020; 72: 1481-1489. DOI: 10.1002/acr.24036.
50.    McNeil JN. *" I noticed something wrong": Lived experiences of women of color who faced a protracted journey to diagnosis with lupus*. Capella University, 2017.